[Effect of a novel fibrinolytic enzyme FA-I on thrombosis and thrombolysis].
OBJECTIVE
To study the effect of FA-I, a novel fibrinolytic enzyme isolated from the metabolite of Arthrobacter sp. DR-536, on thrombosis and thrombolysis in vivo.


METHODS
The anticoagulated blood model of mise were administered with FA-I orally. The venous thrombogenesis inhibition model of rats were administered with FA-I by intestinal route. The carotid thrombosis model of rabbits were given FA-I intravenously. The clotting time (CT), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), Euglobulin lysis time (ELT), fibrinogen (FIG) and hemorheology condition were analyzed.


RESULTS
FA-I prolonged the CT, PT, APTT and TT, and decreased ELT and FIG significantly (P < 0.05 or P < 0.01). FA-I also improved the hemorheology conditions in the rabbits.


CONCLUSIONS
Both intravenous injection and oral administration of FA-I are effective in thrombosis and thrombolysis. FA-I could become a pragmatic venoclysis thrombolytic drug or a peroral thrombolytic drug.
Wang
Gao-xue
GX
College of Animal Science and Technology, Northwest A&F University, Yangling 712100, China.
Liang
Chao-jun
CJ
Yao
Jia-yun
JY
Yuan
Ju-lin
JL
Wang
Jian-fu
JF
D000818:Animals; D001419:Bacteria / Q000201:enzymology*; D001426:Bacterial Proteins / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D002341:Carotid Artery Thrombosis / Q000188:drug therapy*; D004795:Enzyme Stability; D005285:Fermentation; D005341:Fibrinolysin / Q000737:chemistry; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000302:isolation & purification* / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D020246:Venous Thrombosis / Q000188:drug therapy*
D001426:Bacterial Proteins; D005343:Fibrinolytic Agents; D005341:Fibrinolysin